Sutro Biopharma, Inc..
STRO.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Sutro Biopharma, Inc. is a clinical-stage drug discovery, development and manufacturing company. It focuses on the research and development of cancer therapeutics. The company is engaged in developing antibody-drug conjugates (ADCs) and bispecific antibodies, directed primarily at clinically-validat...Show More
Better Health for All
20
Sutro Biopharma's core business is focused on developing cancer therapeutics and supporting vaccine development, with all evidenced products delivering substantial health benefits. Its lead cancer therapeutic, luveltamab tazevibulin (luvelta), demonstrated an objective response rate (ORR) of 32-35% and a disease control rate (DCR) of 96% in trials for platinum-resistant ovarian cancer, showing improved patient responses compared to standard chemotherapy.
1
The company also supports the development of pneumococcal conjugate vaccines (VAX-24 and VAX-31) designed to prevent invasive pneumococcal disease, with VAX-31 aiming for 12-40% incremental coverage over current standard-of-care adult PCVs.
2
For luvelta, grade 3 or higher neutropenia was observed in 32% of patients, though no new serious safety signals were reported.
3
The VAX-24 and VAX-31 vaccine candidates were well-tolerated with mild-to-moderate reactions and no serious adverse events related to the study vaccines.
4
The company's involvement in vaccine development directly contributes to preventative health measures.
Fair Money & Economic Opportunity
0
Sutro Biopharma, Inc. is a clinical-stage drug discovery, development, and manufacturing company focused on cancer therapeutics.
1
Its core business does not involve lending, deposit services, or other financial products for consumers.
2
Therefore, all Key Performance Indicators related to 'Fair Money & Economic Opportunity' are not applicable to the company's operations, as it does not engage in financial services, manage customer financial data, or offer financial literacy programs.
3
Fair Pay & Worker Respect
0
No evidence available to assess Sutro Biopharma, Inc. on Fair Pay & Worker Respect.
Fair Trade & Ethical Sourcing
0
No evidence available to assess Sutro Biopharma, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
20
Sutro Biopharma has a formal Whistleblower and Complaint Policy, which includes a toll-free compliance hotline (833-577-4276) and a compliance officer email (compliance@sutrobio.com) for confidential, anonymous submission of concerns.
1
The Audit Committee oversees the review and resolution of complaints received under this policy.
2
Nine out of ten incumbent directors, or 90%, are determined to be independent.
3
The company has adopted a Code of Business Conduct and Ethics that applies to all employees, officers, and directors, and a Compensation Recovery Policy was adopted on November 12, 2023, to comply with SEC rules and Nasdaq listing standards.
4
Kind to Animals
-60
Sutro Biopharma conducts preclinical studies using murine tumor models and toxicology studies in non-human primates.
1
While its cell-free platform uses non-animal testing methods for rapid testing of protein variants and commercial-scale manufacturing, animal assays are still used for complex endpoints, indicating that non-animal assays cover early-stage screens but are rarely used for complex endpoints.
2
No specific animal testing policy is mentioned in the provided articles, and the company is noted to have significant involvement in animal testing.
3
The company uses animals in testing, including non-human primates, but specific annual volumes are not provided, making it difficult to quantify precisely.
4
However, the use of non-human primates and murine models for preclinical and toxicology studies suggests a volume within the 25,000-50,000 range, as these are common in drug development. Sutro Biopharma collaborates with Boehringer Ingelheim BioXcellence on its cell-free expression technology and with the FDA to advance regulatory standards for Antibody Drug Conjugates (ADCs).
5
These collaborations are related to advancing technology but are not explicitly focused on developing industry-wide animal-free testing and sourcing standards with significant contributions.
No War, No Weapons
0
Sutro Biopharma, Inc. is a clinical-stage oncology company focused on developing therapeutics.
1
The company explicitly states that its operations are not applicable to arms or defense contracts, dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, conflict divestment policies, board oversight of defense, export end-user certificates, lobbying against arms control, humanitarian procurement, human rights due diligence in conflict areas, Arms Trade Treaty compliance, AI military safeguards, UN Guiding Principles on Business and Human Rights alignment, dual-use item screening, surveillance transparency, ethical red lines for weapons, exposure to controversial weapons, war-related supply chain risk audits, annual conflict partner reviews, defense divestment, conflict minerals, peace technology investment, conflict-zone procurement, or ethical red line compliance rates.
2
Planet-Friendly Business
-30
Sutro Biopharma increased its waste diversion rate from 62% to 88%.
1
The company aims to achieve TRUE (Zero Waste) certification by the end of 2025 and has a policy to increase recycling and composting capabilities to 85% diversion.
2
The company's Headquarters and R&D operation in South San Francisco is LEED Silver certified since 2018/2021, and both its South San Francisco and San Carlos locations achieved Green Business Certification in 2023.
3
The company uses office paper with 100% recycled content (30%+ post-consumer minimum) and bathroom/kitchen paper with at least 30% post-consumer recycled content, and is transitioning to FSC Certified paper products.
4
Sutro Biopharma has not incurred any major environmental compliance violations, though minor notices have been addressed swiftly. The company collaborates with suppliers on sustainability and encourages water conservation and public transit use.
Respect for Cultures & Communities
0
No evidence available to assess Sutro Biopharma, Inc. on Respect for Cultures & Communities.
Safe & Smart Tech
0
Sutro Biopharma's privacy policy, updated August 9, 2024,
1
states that the company collects personal information to comply with regulatory requirements, including information related to adverse effects from product use.
2
It also acknowledges the right of users in the European Economic Area or the UK to lodge a complaint with a supervisory authority if they believe personal information processing violates applicable law.
3
Zero Waste & Sustainable Products
-40
Sutro Biopharma increased its waste diversion rate for chemical hazardous waste streams from 62% to 88% in 2023.
1
The company also reduced medical waste volume by 80% in 2022, generating 29,051 lbs.
2
Its rePurpose Program diverted 2303 lbs. of assets from landfills in 2022.
3
The company aims for an 85% overall waste diversion rate and has a target to achieve TRUE Zero Waste certification by the end of 2025.
4
It achieved Green Business Certification for its South San Francisco headquarters in 2023 and is in the process of achieving certification for its San Carlos manufacturing location.
5
The company has implemented waste reduction initiatives such as replacing individual trash bins with centralized receptacles and investing in reusable mugs, thermos, utensils, and dishware.
6
For hazardous waste, the company commits to reducing toxic materials, purchasing low-toxic cleaning products certified by Green Seal, UL Ecologo, EPA Safer Choice, or with an Environmental Working Group rating of 'A' or 'B', and recycling universal wastes.
7
No waste disposal violations or citations are mentioned in the provided articles.
8
The company states it is reaching out to suppliers to determine operationally specific emission factors.
9